Drug Trial Radar · NCT03652064
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
395
Actual
Start
Nov 6, 2018
Primary completion
May 7, 2024
Study completion Apr 21, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
Conditions
- Multiple Myeloma
Interventions
DaratumumabDrug
Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.
BortezomibDrug
Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.
LenalidomideDrug
Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.
DexamethasoneDrug
Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Analysis: Overall Minimal Residual Disease (MRD) Negative RateTime frame: From randomization (Day 1) up to 27.9 months
- Final Progression-Free Survival (PFS) Analysis : Overall Minimal Residual Disease (MRD) Negative RateTime frame: From randomization (Day 1) up to 64.8 months
Locations
114 sites in 13 countries. Site status is shown where the registry gives one.
Innovative Clinical Research Inc
Cerritos, California
Baptist MD Anderson
Jacksonville, Florida
Fort Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana
Norton Healthcare
Louisville, Kentucky
Tufts Medical Center
Boston, Massachusetts
Boston University Medical Center
Boston, Massachusetts
Cancer And Hematology Centers of Western Michigan PC
Grand Rapids, Michigan
Saint Lukes Hospital Saint Lukes Cancer Specialists
Kansas City, Missouri
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
Roswell Park Cancer Institute
Buffalo, New York
NYU Winthrop
Mineola, New York
Levine Cancer Institute
Charlotte, North Carolina
Cleveland Clinic
Cleveland, Ohio
Good Samaritan Hospital Corvallis
Corvallis, Oregon
University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Gibbs Cancer Center
Spartanburg, South Carolina
University of Texas, MD Anderson Cancer Center
Houston, Texas
University of Virginia
Charlottesville, Virginia
Universidade Estadual De Campinas
Campinas, Brazil
Liga Norte Riograndense Contra O Cancer
Natal, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
Porto Alegre, Brazil
Ministerio da Saude Instituto Nacional do Cancer
Rio de Janeiro, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
Rio de Janeiro, Brazil
Instituto de Ensino e Pesquisa São Lucas
São Paulo, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia
São Paulo, Brazil
Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncologia
São Paulo, Brazil
Hospital Santa Cruz
São Paulo, Brazil
Clinica Medica Sao Germano S/S LTDA
São Paulo, Brazil
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
The Gordon & Leslie Diamond Health Care Center
Vancouver, British Columbia, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Brampton Civic Hospital
Brampton, Ontario, Canada
Victoria Hospital
London, Ontario, Canada
Lakeridge Health Oshawa
Oshawa, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
CHU de Quebec L Hotel Dieu de Quebec
Québec, Quebec, Canada
Fakultni nemocnice Brno
Brno, Czechia
Fakultni nemocnice Hradec Kralove
Hradec Králové, Czechia
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.